We chose EGFR as an example for receptor PGx-informed therapy because (1) it is expressed in different cancer types, (2) its mutational landscape is well characterized, (3) aberrantly expressed EGFR is targeted by the majority of tyrosine kinase inhibitors (TKIs), and (4) for a drug target, it has a significant amount of PGx data [128,129,130,131]. The gene discussed is EGFR; the disease is cancer.